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BACKGROUND: The National Colorectal Cancer Roundtable, a national coalition of public, private, and voluntary organizations, has recently
announced an initiative to increase colorectal cancer (CRC) screening rates in the United States to 80% by 2018. The authors evaluated the
potential public health benefits of achieving this goal. METHODS: The authors simulated the 1980 through 2030 United States popula-
tion of individuals aged 50 to 100 years using microsimulation modeling. Test-specific historical screening rates were based on
National Health Interview Survey data for 1987 through 2013. The effects of increasing screening rates from approximately 58% in
2013 to 80% in 2018 were compared to a scenario in which the screening rate remained approximately constant. The outcomes were
cancer incidence and mortality rates and numbers of CRC cases and deaths during short-term follow-up (2013-2020) and extended
follow-up (2013-2030). RESULTS: Increasing CRC screening rates to 80% by 2018 would reduce CRC incidence rates by 17% and mor-
tality rates by 19% during short-term follow-up and by 22% and 33%, respectively, during extended follow-up. These reductions would
amount to a total of 277,000 averted new cancers and 203,000 averted CRC deaths from 2013 through 2030. CONCLUSIONS:
Achieving the goal of increasing the uptake of CRC screening in the United States to 80% by 2018 may have a considerable public
health impact by averting approximately 280,000 new cancer cases and 200,000 cancer deaths within <20 years. Cancer
2015;121:2281-5. VC 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an
open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adapta-
tions are made.
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INTRODUCTION
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in
the United States for both sexes combined, with 136,800 new cancer cases and 50,300 deaths estimated in 2014.1 Registry
data from the past decade indicate that both disease incidence and mortality decreased by approximately 3% per year,2
largely due to the increased use of screening.3,4 Despite the effectiveness of screening and the availability of various screen-
ing options, only 58% of US adults aged 50 to 75 years had received guideline-recommended testing in 2013.5 Previous
studies have demonstrated that a substantial percentage of CRC deaths are attributable to nonuse of screening.6,7 This ral-
lied a recent initiative from the National Colorectal Cancer Roundtable (NCCR), a national coalition of public, private,
and voluntary organizations, to aim for screening rates of 80% in the United States by 2018.8 However, an estimate of the
potential benefits of increasing uptake by an additional 22% in terms of the number of CRC cases and deaths averted is
needed to inform public discourse and policy on this initiative and to project both the short-term and long-term public
health “return on investment.” In the current study, we used advanced modeling approaches to estimate the potential ben-
efits in terms of new CRC cases and deaths averted from achieving the NCCR goal.
MATERIALS AND METHODS
The current study was based on men and women aged 50 to 100 years, and was simulated to match the 1980 through
2030 US population in terms of their life expectancy, risk of CRC, and past and future use of screening. The analyses used
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the Microsimulation Screening Analysis-Colon (MIS-
CAN-COLON) model, which has been used to inform
US Preventive Services Task Force screening
recommendations.9
Microsimulation Model
The MISCAN-COLON model is part of the Cancer
Intervention and Surveillance Modeling Network (CIS-
NET),10 and has been described extensively elsewhere.11
The model integrates the natural history of CRC, its het-
erogeneity, outcomes, and the effects of screening and
treatment. The model allows for the flexible evaluation of
various screening scenarios by leveraging observed data.
The modeled effects of screening demonstrate good con-
cordance with several randomized screening trials.12-16
Source Data
Demography estimates were obtained from the US
Census Bureau.17 Overall life expectancy was based on
generational US life tables from the Berkeley Mortality
Database.18 Age-specific and size-specific prevalence of
adenomas was based on autopsy and colonoscopy data
from before the era of screening.10 Age-, stage-, and
location-specific cancer incidence was based on prescreen-
ing data (years 1975-1979) from the Surveillance, Epide-
miology, and End Results program19; cancer survival was
based on more recent Surveillance, Epidemiology, and
End Results data (years 2000-2010).
Data regarding the historical use of colonoscopy,
fecal occult blood tests, and sigmoidoscopy in the United
States were derived from data from the 1987 through
2013 National Health Interview Survey (NHIS).5 In
2013, 58% of the population aged 50 to 75 years reported
being up-to-date on screening. The percentages that were
up-to-date with each specific test were 54% for colono-
scopy, 8% for fecal occult blood tests, and 4% for
sigmoidoscopy.
Screening Scenarios
In the current analysis, we evaluated a scenario in which
the screening rate increased linearly from 58% in 2013 to
80% in 2018, with no further increase occurring through
2030. We compared this scenario to one in which screen-
ing rates remained constant at approximately 60%. We
evaluated the magnitude of the reduction in CRC inci-
dence and mortality rates per year during both short-term
(2013-2020) and extended (2013-2030) follow-up.
Screening consisted of a mix of colonoscopy, sigmoido-
scopy, and fecal occult blood testing in accordance with
estimates from the NHIS. Patients with a positive fecal
occult blood test or sigmoidoscopy (for adenomas or can-
cer) were referred to diagnostic colonoscopy and patients
in whom adenomas were detected were referred for colo-
noscopic surveillance according to guidelines from the US
Multi-Society Task Force on Colorectal Cancer.20 Patient
adherence to diagnostic colonoscopy and surveillance
colonoscopy was assumed to be 80%.21,22
RESULTS
Incidence Rates and Avoidable New Cancer
Cases
Under the assumption of approximately constant CRC
screening levels in the United States between 2013 and
2030, the crude CRC incidence rate per 100,000 popula-
tion per year would increase from 137 in the first year of
follow-up (2014) to 149 in 2030 (Fig. 1 Top) due to aging
of the population. If screening uptake increased from
58% in 2013 to 80% in 2018, the incidence rates (per
100,000 population) would decrease from 164 in 2014 to
117 in 2030. Compared with a scenario of constant CRC
screening levels, the goal of “80% by 2018” would ini-
tially increase CRC incidence rates by 20% in 2014
Figure 1. Crude colorectal cancer (Top) incidence and (Bot-
tom) mortality rates in the US population aged 50 years,
under 2 scenarios of screening uptake. In the first scenario,
reported screening rates remained at a constant level of
approximately 60% from 2013 through 2030, whereas in the
other scenario, screening rates increased from 60% to 80%
by 2018 and remained constant thereafter.
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because of the early detection of CRC among previously
unscreened individuals, but subsequently decrease the
incidence rates by 17% by 2020 and by 22% by 2030.
With the estimated population of individuals aged 50 to
100 years expected to increase from 108 million in 2014
to 133 million by 2030, the above effects on incidence
and mortality rates would result in 43,000 averted cases
per year by 2030, and a total of 277,000 cases averted
from 2013 through 2030 (Table 1).
Mortality Rates and Avoidable Cancer Deaths
There would be an immediate mortality benefit of
increasing CRC screening rates to 80% by 2018. While
the crude CRC mortality rate per 100,000 population
would increase from 44 in 2014 to 48 in 2030 under con-
stant screening levels of 60%, the mortality rate would
decrease from 43 to 32 with an 80% CRC screening rate
by 2018. Thus, the relative effect of the “80% by 2018”
goal would be a 1% decrease in the CRC mortality rate
by 2014, a decrease of 19% in 2020, and a decrease of
33% in 2030 (Fig. 1 Bottom). This would translate to
21,000 averted cancer deaths per year by 2030, and a
total of 203,000 averted deaths from 2013 through 2030
(Table 1).
DISCUSSION
We used microsimulation modeling to estimate the
potential US public health impact of achieving the
NCCR goal to increase CRC screening rates from <60%
in 2013 to 80% by 2018. The results of the current study
suggest that achieving this goal may produce a reduction
of 22% in CRC incidence rates and 33% in CRC mortal-
ity rates by 2030, which translates to approximately
280,000 averted new cases and 200,000 averted deaths
from 2013 through 2030.
The 20% increase in CRC screening uptake from
60% to 80% has a projected high impact on CRCmortal-
ity (reduction of 33%). This 33% matches well with our
recent estimate that the majority of current CRC mortal-
ity (60%) is attributable to nonuse of screening.7 The
increase in screening uptake from 60% to 80% decreases
the number of underscreened individuals by approxi-
mately 50% and consequently reduces overall CRC mor-
tality by roughly one-half the “population attributable
fraction.”
Within the underscreened population, the impact of
the goal of “80% by 2018” will be larger than the overall
reductions in incidence and mortality of 20% to 30% for
the population because the majority of avoidable cases
and deaths occur within the 40% of the population that is
underscreened. Underscreened individuals tend to have
lower educational levels and income and to lack health in-
surance.23 Thus, a desirable effect of achieving a CRC
screening rate of 80% by 2018 is the potential to reduce
CRC health disparities in the United States, which is an
important Healthy People 2020 objective.24
To our knowledge, no prior study has estimated the
public health benefits of the goal of “80% by 2018.” Sev-
eral studies have estimated the potential contribution of
screening to decreases in CRC incidence and mortality in
the United States.3,4,25,26 The current study estimates of
screening benefits appear to be somewhat smaller than
noted by Ladabaum and Song25 and larger than those
from Edwards et al3 and Yang et al.4 This is likely due to
different study designs or periods, and differences in
assumptions regarding the effectiveness of colonoscopy
screening. For colonoscopy, the effectiveness of screening
is less well established than for other recommended
screening tests due to the absence of evidence from
randomized controlled trials. The effectiveness of endos-
copy screening in the MISCAN-COLON model was
recently increased based on the outcomes of the UK flexi-
ble sigmoidoscopy study.27 This change explains the
slightly higher impact of increasing screening uptake in
this study compared with earlier studies.3,26 We evaluated
a more conservative assumption for colonoscopy efficacy
in which colonoscopy sensitivity for small adenomas was
decreased by 50%; this decreased the impact of a CRC
screening rate of 80% by 2018 on CRC incidence, but
did not appear to substantively influence the mortality
benefits (data not shown).
There are some limitations to the current study.
First, we evaluated only 1 of 2 possible ways to increase
screening rates in the United States, namely by expanding
screening to previously unscreened individuals. An alter-
native way is to reduce the number of individuals who
TABLE 1. Difference in the Number of CRC Cases
and Deaths Per Year When Achieving CRC Screen-
ing Rates of 80% in the United States by 2018,
Compared With Constant Screening Rates of 60%
Calendar Year
2014 2018 2022 2026 2030
Difference in no. of CRC cases (thousands)
Per year 29 27 230 238 243
Cumulative 29 141 28 2112 2277
Difference in no. of CRC deaths (thousands)
Per year 21 27 213 218 221
Cumulative 21 217 260 2123 2203
Abbreviation: CRC, colorectal cancer.
Benefits of 80% CRC Screening by 2018/Meester et al
Cancer July 1, 2015 2283
have been screened but not according to screening recom-
mendations. In the latest NHIS data from 2013, the per-
centage of the population that ever underwent CRC
screening, but not within the recommended intervals, was
7.4%.5 Thus, in a strategy of encouraging both higher
guideline adherence in previously screened individuals
and the participation of previously unscreened individu-
als, the former approach could contribute approximately
one-third (7.4%) to the overall targeted increase of 22%
in screening rates. This may lead to a somewhat lower
public health impact for the “80% by 2018” goal than we
found because the impact of screening is lower in previ-
ously screened individuals compared with unscreened
individuals.
Second, we assumed that the percentage of endos-
copy versus fecal-based examinations and its quality
remained the same in the population when screening
uptake was increased, whereas higher uptake of fecal im-
munochemical testing or other stool-based tests may be
needed to achieve the ideal of an 80% screening rate.28,29
A higher percentage of stool-based tests than was modeled
may affect the projected benefits of increased screening
uptake, although modeling analyses have demonstrated
that the potential benefit of 10-year colonoscopy and an-
nual fecal immunochemical testing may be comparable.9
Colonoscopy quality is known to vary widely among pro-
viders and is highly correlated with disease outcomes.30 If
expanding screening, in part, was achieved through exam-
iners with lower detection rates, then the benefits may be
less than projected.
Finally, there may be CRC disparities between
screened and underscreened populations beyond those at-
tributable to screening.31 If the background CRC risk in
the underscreened population is higher and/or CRC sur-
vival is poorer, the impact of reaching an 80% screening
rate by 2018 may be even larger.
The outcomes of the current study were confined to
CRC incidence and mortality in the population, and did
not include years of life lost to CRC, costs, and potential
harms of screening. Previous analyses have indicated that
CRC screening is likely highly cost-effective,11,32 and may
even be cost-saving,33 making increasing screening not
only desirable from a perspective of cancer control but
also from a financial perspective. However, these analyses
usually do not consider potential overuse of screening and
surveillance,34 program costs,35 and especially resources
needed to bring in the individuals to reach a goal of 80%
uptake of screening.
There are many barriers to increasing CRC screen-
ing uptake in the United States, only some of which are
the target of health care reforms under the Patient Protec-
tion and Affordable Care Act.36,37 Substantial coordi-
nated effort is needed to achieve the goal of an 80% CRC
screening rate by 2018 in the United States. The results of
the current study indicate that such investments may be
well rewarded with long-term reductions in CRC inci-
dence and mortality rates of 22% and 33%, respectively,
and the avoidance of 280,000 new CRC cases and
200,000 CRC deaths in<20 years.
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